Overview

Open-Label Safety Study of AXS-05 in Subjects With TRD

Status:
Enrolling by invitation
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with treatment resistant depression (TRD).
Phase:
Phase 2
Details
Lead Sponsor:
Axsome Therapeutics, Inc.
Treatments:
Bupropion
Dextromethorphan